NCT06427083View on ClinicalTrials.gov

Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Envlo Tablet

Enavogliflozin 0.3mg

DRUG

Envolomet SR Tablet

Enavogliflozin 0.3mg/Metformin1,000mg

Trial Locations (1)

Unknown

Kyung Hee University Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY